Biohaven Ltd. $BHVN Shares Purchased by EFG Asset Management North America Corp.

Key Points

• EFG Asset Management North America Corp. increased its stake in Biohaven Ltd. by 59.2% in the 1st quarter, now owning approximately 0.09% of the company worth about $2.17 million.
• Other institutional investments include a 319.8% increase by Parallel Advisors LLC and considerable new positions from SVB Wealth LLC and IFP Advisors Inc.
• Biohaven has a current market capitalization of $1.70 billion and is experiencing fluctuations in stock rating, with an average target price of $55.71 from analysts.

EFG Asset Management North America Corp. increased its holdings in Biohaven Ltd. (NYSE:BHVN - Free Report) by 59.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,264 shares of the company's stock after acquiring an additional 33,551 shares during the period. EFG Asset Management North America Corp. owned about 0.09% of Biohaven worth $2,169,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Ameriprise Financial Inc. raised its position in shares of Biohaven by 40.0% in the fourth quarter. Ameriprise Financial Inc. now owns 508,682 shares of the company's stock worth $18,994,000 after buying an additional 145,331 shares in the last quarter. KBC Group NV lifted its holdings in shares of Biohaven by 35.0% during the first quarter. KBC Group NV now owns 4,560 shares of the company's stock valued at $110,000 after purchasing an additional 1,183 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Biohaven by 319.8% during the first quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock valued at $33,000 after purchasing an additional 1,036 shares during the last quarter. SG Americas Securities LLC raised its holdings in Biohaven by 155.8% in the 1st quarter. SG Americas Securities LLC now owns 23,029 shares of the company's stock worth $554,000 after acquiring an additional 14,028 shares during the last quarter. Finally, Fiera Capital Corp purchased a new position in Biohaven in the 1st quarter worth approximately $13,983,000. 88.78% of the stock is owned by institutional investors.

Biohaven Stock Performance

BHVN traded down $0.34 on Wednesday, reaching $14.15. The stock had a trading volume of 731,700 shares, compared to its average volume of 1,724,860. The company has a market cap of $1.50 billion, a P/E ratio of -1.85 and a beta of 1.02. The business's 50-day moving average price is $14.65 and its two-hundred day moving average price is $18.97. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 1.91. Biohaven Ltd. has a 12-month low of $12.79 and a 12-month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.94) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.94). Sell-side analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Cantor Fitzgerald raised shares of Biohaven to a "strong-buy" rating in a research report on Tuesday, May 13th. Robert W. Baird decreased their price target on shares of Biohaven from $57.00 to $52.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Leerink Partners decreased their price target on shares of Biohaven from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Bank of America decreased their target price on shares of Biohaven from $50.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Finally, Raymond James Financial upgraded shares of Biohaven from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, September 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $55.71.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.